A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study with an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects with Psoriatic Arthritis.

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study with an Open Label Extension to Evaluate the Safety and Efficacy of AMG 827 in Subjects with Psoriatic Arthritis.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2016

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 28 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
    • 14 Jun 2014 Results presented at the 15th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top